Published Technical Disclosure Archive

Enhanced Fractionated Radiotherapy and Chemotherapy with Oxygen Therapeutic and Radiosensitizers

Publication ID: 24-11857627_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Fractionated Radiotherapy and Chemotherapy with Oxygen Therapeutic and Radiosensitizers,” Published Technical Disclosure No. 24-11857627_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857627_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,627.

Summary of the Inventive Concept

This inventive concept combines oxygen therapeutics with radiosensitizers and hypoxia-activated prodrugs to enhance the efficacy of fractionated radiotherapy and chemotherapy for treating glioblastoma.

Background and Problem Solved

The original patent disclosed the use of oxygen therapeutics in combination with repeated administrations of chemotherapy medications and/or radiation therapy. However, the patent did not address the limitations of radiosensitizers and hypoxia-activated prodrugs in enhancing the treatment outcome. This inventive concept solves the problem by introducing simultaneous administration of radiosensitizers and hypoxia-activated prodrugs with oxygen therapeutics, thereby increasing the efficacy of the treatment.

Detailed Description of the Inventive Concept

The inventive concept involves administering a water emulsion of perfluoropentane and a radiosensitizer simultaneously to a subject suffering from glioblastoma. The radiosensitizer enhances the sensitivity of tumor cells to radiation therapy, while the oxygen therapeutic increases oxygenation of the tumor cells. Additionally, the inventive concept includes administering a hypoxia-activated prodrug that is activated by the oxygenation of the tumor cells, further enhancing the treatment outcome. The system for treating glioblastoma comprises a multi-fraction radiotherapy or chemotherapy apparatus, a perfluoropentane emulsion administration device, and a radiosensitizer administration device.

Novelty and Inventive Step

The simultaneous administration of radiosensitizers and hypoxia-activated prodrugs with oxygen therapeutics is a novel and non-obvious improvement over the original patent, providing a significant enhancement in the treatment outcome.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include administering the radiosensitizer and hypoxia-activated prodrug sequentially, or using different types of oxygen therapeutics and radiosensitizers. Variations of the system include using different administration devices and apparatuses.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the treatment of glioblastoma and other solid tumors, with a target market in the pharmaceutical and medical device industries.

CPC Classifications

SectionClassGroup
A A61 A61K41/0038
A A61 A61K9/0019
A A61 A61K9/107
A A61 A61K31/02
A A61 A61K33/00
A A61 A61K39/395
A A61 A61K45/06
A A61 A61K47/10
A A61 A61K47/24
A A61 A61K47/26
A A61 A61N5/10
A A61 A61K2039/505
A A61 A61K2039/545
A A61 A61N2005/1098

Field of Art

Oncological therapeutics, specifically targeted cancer treatment methods involving radiotherapy, chemotherapy, and oxygen therapeutics, with expertise in pharmaceutical formulations, drug delivery systems, and cancer treatment protocols

Person of Ordinary Skill (PHOSITA) Profile

A medical researcher or oncological pharmacologist with advanced training in cancer therapeutics, possessing knowledge of radiation sensitization techniques, drug delivery mechanisms, and combinatorial treatment strategies for glioblastoma

Obviousness Rationale

A person having ordinary skill would recognize that combining oxygen therapeutics with radiosensitizers and hypoxia-activated prodrugs represents a logical extension of the source patent's core methodology of enhancing radiation therapy through oxygenation. The PTD's variations demonstrate predictable combinations of known therapeutic techniques targeting tumor microenvironment optimization. These modifications represent incremental improvements that would be apparent to a skilled practitioner seeking to enhance treatment efficacy.

Obvious Combinations & Variations

Source Patent Element
Perfluoropentane water emulsion for increasing tumor oxygenation during radiotherapy
PTD Variation
Adding simultaneous radiosensitizer administration to enhance tumor cell radiation sensitivity
Obviousness Reasoning
Known technique of combining complementary therapeutic agents to improve treatment outcomes, with predictable synergistic effects on tumor cell destruction
Source Patent Element
Intravenous administration of oxygen therapeutic for glioblastoma treatment
PTD Variation
Incorporating hypoxia-activated prodrugs that become active with increased tumor oxygenation
Obviousness Reasoning
Finite set of logical modifications to exploit enhanced tumor oxygenation, representing a standard design approach in targeted cancer therapeutics
Source Patent Element
Multi-fraction radiotherapy method for glioblastoma treatment
PTD Variation
Conjugating radiosensitizers to tumor-specific monoclonal antibodies for targeted delivery
Obviousness Reasoning
Well-established approach in oncological drug design to improve specificity and reduce systemic toxicity, using known antibody-drug conjugation techniques
Source Patent Element
Water emulsion containing perfluoropentane for cancer treatment
PTD Variation
Developing alternative administration protocols and device configurations for drug delivery
Obviousness Reasoning
Predictable engineering variations representing standard optimization strategies in medical device and pharmaceutical formulation development
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857627, the present publication demonstrates that the claimed variations in glioblastoma treatment methodology would have been obvious to a person having ordinary skill in the art at the time of invention. The disclosed combinations of oxygen therapeutics, radiosensitizers, and targeted delivery mechanisms represent incremental, predictable modifications that do not rise to the level of non-obvious innovation, thus rendering potential derivative claims anticipated and obvious under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,627
TitleFractionated radiotherapy and chemotherapy with an oxygen therapeutic
Assignee(s)NuvOx Pharma LLC